Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 45

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
    2025  
    2024  
    Change 
  
    Dental 
    $427,297  
    $638,226  
    $(210,929)
  
    Medical 
     9,838  
     3,009  
     6,829 
  
    Corporate 
     -  
     -  
     - 
  
    Total research and development 
    $437,135  
    $641,235  
    $(204,100)

Consolidated research and development (R&D) expenses for the nine months
ended September 30, 2025, were approximately $437,000, compared to $641,000 for the same period in 2024, representing a decrease of approximately
$204,000, or 32%. The decrease primarily reflects the Company’s decision to delay development activities related to the next-generation
STA Single Tooth Anesthesia System®.

This strategic decision allows the Company to conserve resources and prioritize
commercialization efforts for its existing product portfolio, including the continued expansion of the CompuFlo® Epidural and CathCheck®
Systems, while maintaining the flexibility to resume product development as market conditions and business priorities warrant.

 24 

Profit
(Loss) from Operations for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $1,328,199  
    $1,526,020  
    $(197,821)
  
    Medical 
     (1,121,237) 
     (1,349,811) 
     228,574 
  
    Corporate 
     (4,823,917) 
     (4,890,879) 
     66,962 
  
    Total loss from operations 
    $(4,616,955) 
    $(4,714,670) 
    $97,715 

The loss from operations for the nine months ended September 30, 2025,
was approximately $4.6 million, compared to $4.7 million for the same period in 2024, representing an improvement of approximately $98,000,
or 2%. The modest improvement primarily reflects lower research and development (R&D) expenses during the period, partially offset
by slightly higher consulting, professional, and regulatory costs within selling, general, and administrative (SG&A) expenses